Skip to main content

Advertisement

SpringerLink
Log in

The epithelial cadherin –160C/A polymorphism is associated with decreased risk of colorectal cancer: a case–control study

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

The epithelial cadherin (CDH1) is an important determinant of tumor progression. Previous studies have indicated that the CDH1 –160C/A polymorphism was associated with the risk of colorectal cancer (CRC). However, they yielded conflicting results. Thus, we conducted this case–control study to evaluate the association between the CDH1 –160C/A polymorphism and susceptibility to CRC in a Chinese population. We recruited 351 cases and 411 controls in this case–control study. The genotype of the CDH1 –160C/A polymorphism was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOFMS). This study found that the CDH1 –160C/A polymorphism was associated with decreased risk of CRC in this Chinese Han population. Subgroup analyses showed that the CDH1 –160C/A polymorphism decreased the risk of CRC among the males and non-drinkers. In addition, a significantly decreased risk was observed in CRC patients with tumor size ≤ 5 cm, and AA genotype showed a protective role in the CRC patients with no lymph node metastasis. In conclusion, this study shows that CDH1 –160C/A polymorphism is associated with decreased risk of CRC in a Chinese Han population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anvarnia A, Mohaddes-Gharamaleki F, Asadi M, Akbari M, Yousefi B, Shanehbandi D. Dysregulated microRNAs in colorectal carcinogenesis: new insight to cell survival and apoptosis regulation. J Cell Physiol. 2019. https://doi.org/10.1002/jcp.28872.

    Article  PubMed  Google Scholar 

  2. Yarla NS, Gali H, Pathuri G, et al. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention. Semin Cancer Biol. 2019;56:168–74. https://doi.org/10.1016/j.semcancer.2018.08.011.

    Article  CAS  PubMed  Google Scholar 

  3. Robertson DJ, Ladabaum U. Opportunities and challenges in moving from current guidelines to personalized colorectal cancer screening. Gastroenterology. 2019;156:904–17. https://doi.org/10.1053/j.gastro.2018.12.012.

    Article  PubMed  Google Scholar 

  4. Peng L, Weigl K, Boakye D, Brenner H. Risk scores for predicting advanced colorectal neoplasia in the average-risk population: a systematic review and meta-analysis. Am J Gastroenterol. 2018;113:1788–800. https://doi.org/10.1038/s41395-018-0209-2.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Wong MCS, Chan CH, Lin J, et al. Lower relative contribution of positive family history to colorectal cancer risk with increasing age: a systematic review and meta-analysis of 9.28 million individuals. Am J Gastroenterol. 2018;113:1819–27. https://doi.org/10.1038/s41395-018-0075-y.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Nakarai C, Osawa K, Akiyama M, et al. Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer. Clin Exp Med. 2015;15:333–41. https://doi.org/10.1007/s10238-014-0298-1.

    Article  CAS  PubMed  Google Scholar 

  7. Vanova B, Kalman M, Jasek K, et al. Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer. Clin Exp Med. 2019;19:219–24. https://doi.org/10.1007/s10238-019-00545-y.

    Article  CAS  PubMed  Google Scholar 

  8. Lasabova Z, Kalman M, Holubekova V, et al. Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing. Clin Exp Med. 2019;19:393–400. https://doi.org/10.1007/s10238-019-00558-7.

    Article  PubMed  Google Scholar 

  9. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85. https://doi.org/10.1056/NEJM200007133430201.

    Article  CAS  PubMed  Google Scholar 

  10. Li Y, Liang J, Kang S, et al. E-cadherin gene polymorphisms and haplotype associated with the occurrence of epithelial ovarian cancer in Chinese. Gynecol Oncol. 2008;108:409–14. https://doi.org/10.1016/j.ygyno.2007.10.024.

    Article  CAS  PubMed  Google Scholar 

  11. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: How does cadherin dysfunction promote tumor progression? Oncogene. 2008;27:6920–9. https://doi.org/10.1038/onc.2008.343.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Pecina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 2003;3:17. https://doi.org/10.1186/1475-2867-3-17.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Li LC, Chui RM, Sasaki M, et al. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res. 2000;60:873–6.

    CAS  PubMed  Google Scholar 

  14. Porter TR, Richards FM, Houlston RS, et al. Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene. 2002;21:1928–33. https://doi.org/10.1038/sj.onc.1205245.

    Article  CAS  PubMed  Google Scholar 

  15. Tan XL, Nieters A, Kropp S, Hoffmeister M, Brenner H, Chang-Claude J. The association of cyclin D1 G870A and E-cadherin C-160A polymorphisms with the risk of colorectal cancer in a case control study and meta-analysis. Int J Cancer. 2008;122:2573–80. https://doi.org/10.1002/ijc.23363.

    Article  CAS  PubMed  Google Scholar 

  16. de Lima JM, de Souza LG, da Silva ID, Forones NM. E-cadherin and metalloproteinase-1 and -7 polymorphisms in colorectal cancer. Int J Biol Markers. 2009;24:99–106.

    Article  Google Scholar 

  17. Shin Y, Kim IJ, Kang HC, et al. A functional polymorphism (− 347 G –> GA) in the E-cadherin gene is associated with colorectal cancer. Carcinogenesis. 2004;25:2173–6. https://doi.org/10.1093/carcin/bgh223.

    Article  CAS  PubMed  Google Scholar 

  18. Bahadir A, Eral G, Budak M, et al. Association of clinicopathological features with E-cadherin (CDH1) gene-160 C > A promoter polymorphism in Turkish colorectal cancer patients. J Cancer Res Ther. 2019;15:26–31. https://doi.org/10.4103/jcrt.JCRT_1277_16.

    Article  CAS  PubMed  Google Scholar 

  19. Pittman AM, Twiss P, Broderick P, et al. The CDH1-160C > A polymorphism is a risk factor for colorectal cancer. Int J Cancer. 2009;125:1622–5. https://doi.org/10.1002/ijc.24542.

    Article  CAS  PubMed  Google Scholar 

  20. Cattaneo F, Venesio T, Molatore S, et al. Functional analysis and case-control study of -160C/A polymorphism in the E-cadherin gene promoter: association with cancer risk. Anticancer Res. 2006;26:4627–32.

    CAS  PubMed  Google Scholar 

  21. Rivu SF, Apu MNH, Shabnaz S, et al. Association of TP53 codon 72 and CDH1 genetic polymorphisms with colorectal cancer risk in Bangladeshi population. Cancer Epidemiol. 2017;49:46–52. https://doi.org/10.1016/j.canep.2017.05.005.

    Article  PubMed  Google Scholar 

  22. Grunhage F, Jungck M, Lamberti C, et al. Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis. 2008;23:147–54. https://doi.org/10.1007/s00384-007-0388-6.

    Article  PubMed  Google Scholar 

  23. Wang Y, Yang H, Li L, Wang H, Zhang C, Xia X. E-cadherin (CDH1) gene promoter polymorphism and the risk of colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2012;27:151–8. https://doi.org/10.1007/s00384-011-1320-7.

    Article  PubMed  Google Scholar 

  24. Sun N, Chen J, Hu G, et al. Association between the Epithelial Cadherin - 160C/A polymorphism and colorectal cancer risk: evidence from a meta-analysis. Crit Rev Eukaryot Gene Expr. 2017;27:347–54. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2017020525.

    Article  PubMed  Google Scholar 

  25. Geng P, Chen Y, Ou J, Yin X, Sa R, Liang H. The E-cadherin (CDH1) -C160A polymorphism and colorectal cancer susceptibility: a meta-analysis. DNA Cell Biol. 2012;31:1070–7. https://doi.org/10.1089/dna.2011.1380.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Author notes

  1. Wenhuan Li and Deshuang Xiao contribute to this study equally.

Authors and Affiliations

  1. Department of Gastrointestinal Surgery, The Affliated Wenling Hospital of Wenzhou Medical University, The First People’s Hospital of Wenling, No. 333 Chuan’an South Road, Chengxi Street, Wenling, Taizhou, China

    Wenhuan Li & Huawen Wu

  2. Department of Liver and Gallbladder Surgery, The Affliated Wenling Hospital of Wenzhou Medical University, The First People’s Hospital of Wenling, No. 333 Chuan’an South Road, Chengxi Street, Wenling, Taizhou, China

    Deshuang Xiao

  3. Department of Surgery, The Affliated Wenling Hospital of Wenzhou Medical University, The First People’s Hospital of Wenling, No. 333 Chuan’an South Road, Chengxi Street, Wenling, Taizhou, China

    Lewei Xu

Authors
  1. Wenhuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deshuang Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huawen Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lewei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Wenhuan Li conceived and designed the experiments. Huawen Wu performed the experiments. Lewei Xu analyzed the data. Deshuang Xiao contributed reagents/materials/analysis tools. Lewei Xu and Wenhuan Li wrote the paper.

Corresponding author

Correspondence to Lewei Xu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration.

Informed consent

Informed consents were obtained from the study participants. The study protocol was confirmed by the Ethics Committee of the Affliated Wenling Hospital of Wenzhou Medical University, the First People’s Hospital of Wenling.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, W., Xiao, D., Wu, H. et al. The epithelial cadherin –160C/A polymorphism is associated with decreased risk of colorectal cancer: a case–control study. Clin Exp Med 20, 73–78 (2020). https://doi.org/10.1007/s10238-019-00586-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-019-00586-3

Keywords

Search

Navigation